Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidating Financial Statements - Additional Information (Details)

v3.24.2.u1
Condensed Consolidating Financial Statements - Additional Information (Details)
Sep. 08, 2020
USD ($)
Debtinstrument
Jan. 21, 2020
USD ($)
Debtinstrument
Jun. 30, 2024
USD ($)
Iterum Therapeutics Bermuda Limited      
Condensed Financial Statements Captions [Line Items]      
Ownership percentage   100.00%  
Subsidiary Guarantors      
Condensed Financial Statements Captions [Line Items]      
Ownership percentage   100.00%  
2025 Exchangeable Notes      
Condensed Financial Statements Captions [Line Items]      
Aggregate principal amount   $ 9,891,000 $ 11,117,000
Private Placement | 2025 Exchangeable Notes      
Condensed Financial Statements Captions [Line Items]      
Aggregate principal amount   51,588,000  
Debt instrument price per unit $ 1,000 1,000  
Private Placement | RLNs      
Condensed Financial Statements Captions [Line Items]      
Aggregate principal amount   $ 103,000  
Number of debt instruments within each notes | Debtinstrument 50 50  
Rights Offering | 2025 Exchangeable Notes      
Condensed Financial Statements Captions [Line Items]      
Aggregate principal amount $ 220,000    
Rights Offering | RLNs      
Condensed Financial Statements Captions [Line Items]      
Aggregate principal amount $ 440